Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
about
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyScoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysisDeterminants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD).Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrPharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia.Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationReduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.Mesenchymal stromal cells: a new tool against graft-versus-host disease?Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell TransplantResults from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool.The evolution of hematopoietic SCT in myelodysplastic syndrome.Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.In vivo protection of activated Tyr22-dihydrofolate reductase gene-modified canine T lymphocytes from methotrexate.Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification.Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.The Effect of GVHD on Long-term Outcomes after Peripheral Blood Allogeneic Stem Cell Transplantation from an HLA-identical Sibling in Adult Acute Lymphocytic Leukemia: A Landmark Analysis Approach in Competing Risks.Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).New ways to separate graft-versus-host disease and graft-versus-tumour effects after allogeneic haematopoietic stem cell transplantation.Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.Reduced-intensity conditioned allogeneic SCT in adults with AML.Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
P2860
Q27010653-1AABD520-929E-4213-94FC-F65C6DA1BAD3Q30353404-C2DA1131-62FC-447C-B3E8-A104B8E5217DQ33689153-C4633EBB-8A97-448F-B99F-C95247FAD6E3Q33774650-AE6A1C87-DE4F-4166-AC2C-C4DD0B932829Q33886217-CEB61E7E-9708-4ED5-B313-E51066E3832DQ33990856-B7D5A715-A0C6-4D4E-AA85-E2A31861C345Q34044024-28B735C1-1B52-4ACF-BF0D-E9DEFD7CACD7Q34220717-BD9887C3-6A30-4956-8E28-3C6BEE89FF51Q34380060-9BFB4E46-9B34-4BCB-8044-661BD62C4E89Q34667853-4FB27E0F-4B07-4913-A899-692CC21BB16AQ35202588-4D0068FF-AF66-454A-9B83-7DCC2FF11627Q35571053-2E687531-464F-4BB7-8C2D-5B51DBF6EC4EQ35800814-7999EB7B-62EA-40C6-A348-F11108F773EAQ35848391-0B7E4C0D-6FD0-419B-A91D-9E22D7C925AFQ35975019-41210D53-6888-4C60-92BF-D4AAD0C3A680Q36036328-6D14D3ED-E3AE-4C1C-8FE9-0A746EB0916EQ36862464-BF6DBC8B-711B-40E3-B4C4-9569EB884E90Q37148409-891B605A-863D-43F7-9E8B-302917B7A94DQ37159533-A78DAA05-45A5-400F-B479-D2B4736741FFQ37291642-3F364832-CD2E-4E87-B2DB-050C904AEFEBQ37390890-4930AC08-F678-4313-9B5A-003F84601093Q37404489-D518DFCA-2EFA-4468-8BBD-A1857DA493C7Q37429911-56835FB0-F1E0-4941-BDB8-D28D94F732C4Q37457900-F17698E0-7572-4FC8-A95A-585265488641Q37559330-261EBE64-E912-4651-8741-D70524209A63Q37592994-1C9450E3-109F-4357-BBED-E6FAE10D3585Q37618811-B7C53161-33E7-43FE-B981-3FB879B0F5F1Q37718826-64E6E0E7-32E8-4CA3-9795-466100833590Q37730059-D585E453-76D1-4716-A98F-30C8BE181588Q37810098-188EF2CB-141F-4AF5-A829-0D34C383190EQ37942816-14CE1C7C-402E-4210-8EBB-003055943A37Q38029953-739D362C-7C1F-46CE-843F-B74FCCD43A02Q38057376-5538CB74-FA6A-4B4C-A29E-A557A16E5379Q38095833-7A9EBE12-0CDA-43CE-AE70-9C93115CEEEEQ38161965-04684D35-F7FD-4FAB-BABA-A173272230E2Q38207595-3D461AF3-1997-4B28-AC28-0C3E3ABC3C42Q38248427-54469C4E-C2A7-49DE-BADA-55507C6EEAEDQ38366632-3BDE402B-FB53-4C97-AE17-8ED17BB240C7Q38479720-35531B34-35BF-49DE-AE00-AA3464B9E790Q38488058-815A2B81-7134-4178-94B7-70B8DCEBC026
P2860
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Sustained remissions of high-r ...... est factor improving survival.
@en
Sustained remissions of high-r ...... est factor improving survival.
@nl
type
label
Sustained remissions of high-r ...... est factor improving survival.
@en
Sustained remissions of high-r ...... est factor improving survival.
@nl
prefLabel
Sustained remissions of high-r ...... est factor improving survival.
@en
Sustained remissions of high-r ...... est factor improving survival.
@nl
P2093
P356
P1476
Sustained remissions of high-r ...... gest factor improving survival
@en
P2093
Antonia Sampol
Christelle Ferra
Dolores Caballero
Dolores Carrera
Jesus Martin
Joan Besalduch
Jorge Sierra
Jose A Perez-Simón
Jose B Nieto
Jose M Moraleda
P304
P356
10.1200/JCO.2007.11.1641
P407
P577
2007-12-17T00:00:00Z